General Information of Drug (ID: DMLYAGD)

Drug Name
JNJ-64264681 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
PubChem CID
129234005
TTD Drug ID
DMLYAGD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibrutinib DMHZCPO Mantle cell lymphoma 2A85.5 Approved [3]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [4]
Zanubrutinib DMJWRQP Mantle cell lymphoma 2A85.5 Approved [5]
Pirtobrutinib DMRG1X3 Non-hodgkin lymphoma 2B33.5 Approved [6]
GDC-0853 DMBEL3Q Multiple sclerosis 8A40 Phase 3 [7]
ICP-022 DMU72KL Chronic lymphocytic leukaemia 2A82.0 Phase 3 [8]
Tolebrutinib DML19V6 Multiple sclerosis 8A40 Phase 3 [9]
CC-292 DMJR9H0 Chronic lymphocytic leukaemia 2A82.0 Phase 2 [10]
BMS-986142 DMZB8AJ Rheumatoid arthritis FA20 Phase 2 [7]
LOU064 DME8O5K Chronic idiopathic urticaria EB00.1 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04210219) A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
2 A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
4 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6 Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of InnoCare Pharma.
9 Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
10 Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)